ClinicalTrials.Veeva

Menu

Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CAD

N

National and Kapodistrian University of Athens

Status

Unknown

Conditions

Amyloid
Diabetes
Insulin Resistance
Clopidogrel Resistance

Study type

Observational

Funder types

Other

Identifiers

NCT04027712
LTA_MOTS-c_bamyloid_DM_CAD

Details and patient eligibility

About

Increased circulating b-amyloid and decreased Mitochondrial-derived peptide (MOTS-c), a peptide improving tissue insulin sensitivity, are reported in diabetes. The investigators plan to investigate the association of both biofactors with high on-clopidogrel platelet reactivity and cardiovascular mortality in type 2 diabetic patients with Coronary artery disease

Full description

In type II diabetic patients with Coronary artery disease treated with clopidogrel and aspirin, the investigators plan to measure: i. maximum platelet aggregation to adenosine diphosphate (ADP) by Light Transmission Aggregometry (LTAmax), as a marker of on-clopidogrel treatment platelet reactivity ii. Malondialdehyde (MDA), as oxidative stress marker, Mitochondrial-derived peptide MOTS-c and b-amyloid. blood levels.

Enrollment

120 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • type 2 diabetic patients with coronary artery disease, documented by coronary angiography,
  • both per os or/and parenteral antidiabetic medications and double antiplatelet therapy (DAPT), constituted by a daily dose of 100 mg acetylsalicylic acid per os and a daily dose of 75 mg clopidogrel per os should be prescribed to the patients for at least one month before inclusion in the study

Exclusion criteria

  • abnormal renal function (creatinine> 2.5 mg / dl),
  • hepatic failure (bilirubin> 2 mg / dl),
  • active malignancy,
  • patients treated with drugs that affect platelet function, besides aspirin 100 mg qd and clopidogrel 75 mg qd,
  • patients with a history of hemorrhagic mood,
  • patients with thrombocytopenia (PLTs < 100x109 / L) and
  • anemia (HCT <28%).

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems